[go: up one dir, main page]

KR910700259A - How T-cell Recognized Peptide Modifications Influence the Immune Response - Google Patents

How T-cell Recognized Peptide Modifications Influence the Immune Response

Info

Publication number
KR910700259A
KR910700259A KR1019900702013A KR900702013A KR910700259A KR 910700259 A KR910700259 A KR 910700259A KR 1019900702013 A KR1019900702013 A KR 1019900702013A KR 900702013 A KR900702013 A KR 900702013A KR 910700259 A KR910700259 A KR 910700259A
Authority
KR
South Korea
Prior art keywords
lys
peptide
thr
derivative
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900702013A
Other languages
Korean (ko)
Inventor
엑클 데이비드 디
고르스키 잭
알. 램 조나단
로트바드 조나단
Original Assignee
리차드 이. 림바크
더 블러드 센터 오브 사우드이스턴 위스콘신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리차드 이. 림바크, 더 블러드 센터 오브 사우드이스턴 위스콘신 filed Critical 리차드 이. 림바크
Publication of KR910700259A publication Critical patent/KR910700259A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음.No content.

Description

T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법How T-cell Recognized Peptide Modifications Influence the Immune Response

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (11)

내부 펩티드 대신 MHC결합부위에 사용될 수 있는 대체용 펩티드를 포유동물에 투여하되, 상기 대체용 펩티드를 내부 펩티드 복합체인 MHC 클래스 II 분자에 대한 T-세포인지를 조절할 수 있는 양을 포유동물에 투여하여서 되는 포유동물에 면역반응을 일으키는 방법.By administering to the mammal a replacement peptide that can be used for the MHC binding site instead of an internal peptide, and administering the replacement peptide to the mammal in an amount capable of controlling the T-cell recognition of the MHC class II molecule, To produce an immune response in a mammal. 제1항에 있어서, 상기 대체용 펩티드가 HA단백질 유도체인, 포유동물에 면역반응을 일으키는 방법.The method of claim 1, wherein the replacement peptide is an HA protein derivative. 제2항에 있어서, 상기 유도체는 아미노산 시퀀스 Cys-Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr-Gly(I)로 이루어진 포유동물에 면역반응을 일으키는 방법.The method of claim 2, wherein the derivative is immune to a mammal consisting of the amino acid sequence Cys-Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr-Gly (I). How to cause it. 제2항에 있어서, 상기 유도체는 아미노산 시퀀스 Lys-Tyr-Val-Lgs-Gln-Asn-Thr-Leu-Lys--Leu-Ala-Thr(II)로 이루어진 포유동물에 면역 반응을 일으키는 방법.The method of claim 2, wherein said derivative comprises an amino acid sequence Lys-Tyr-Val-Lgs-Gln-Asn-Thr-Leu-Lys--Leu-Ala-Thr (II). 제4항에 있어서, 상기 유도체는 하나, 둘 또는 세 개의 잔기가 치환된 아미노산 시퀀스인 포유동물에 면역 반응을 일으키는 방법.The method of claim 4, wherein said derivative is an amino acid sequence in which one, two or three residues are substituted. 내부 펩티드 대신 MHC결합부위에 사용될 수 있는 대체용 펩티드를 MHC 클래스 II 분자인 내부 펩티드 복합체에 대한 T-세포 인지를 조절할 수 있게 유효량 함유하여서 되는 포유동물에 면역반응을 일으키는 약제학적 조성물.A pharmaceutical composition for causing an immune response to a mammal, comprising an effective amount of a replacement peptide that can be used at the MHC binding site instead of the internal peptide so as to control T-cell recognition of the internal peptide complex, which is an MHC class II molecule. 제6항에 있어서, 상기 대체용 펩티드는 HA단백질 유도체인, 포유동물에 면역반응을 일으키는 약제학적 조성물.The pharmaceutical composition of claim 6, wherein the replacement peptide is an HA protein derivative. 제7항에 있어서 상기 유도체인 아미노산 시퀀스 Cys-Pro-Lys-Thr-Val-Lys-Gln-Asn-Thr-Leuu-Ala-Thr-Gly(I)로 이루어진 포유동물에 면역반응을 일으키는 약제학적 조성물.The pharmaceutical composition according to claim 7, wherein said derivative is an amino acid sequence Cys-Pro-Lys-Thr-Val-Lys-Gln-Asn-Thr-Leuu-Ala-Thr-Gly (I). . 제7항에 있어서, 상기 유도체는 아미노산 시퀀스 Lys-Tyr-Val-Lys-Gln-Asn-Tyr-Leu-Lys-Leur(II)로 이루어진 포유동물에 면역반응을 일으키는 약제학적 조성물.8. The pharmaceutical composition of claim 7, wherein said derivative comprises an amino acid sequence Lys-Tyr-Val-Lys-Gln-Asn-Tyr-Leu-Lys-Leur (II). 제9항에 있어서, 상기 유도체는 하나, 둘 또는 세 개의 잔기가 치환된 아미노산 시퀀스인 포유동물에 면역반응을 일으키는 약제학적 조성물.The pharmaceutical composition of claim 9, wherein the derivative is an amino acid sequence in which one, two or three residues are substituted. 대상 포유동물의 면역반응에 영향을 주기 위하여 내부 펩티드 복합체인 MHC 클래스 II 분자의 T-세포인지를 변형하는데 충분한 양의 대체용 펩티드를 상기 대상에 투여하는데 사용되는 약제 제조시 내부 펩티드 대신 MHC 결합부위에 사용할 수 있는 대체용 펩티드를 약제학적 양으로 사용되는 방법.MHC binding sites in place of internal peptides in the manufacture of a medicament used to administer to the subject an amount of a replacement peptide sufficient to modify the T-cell recognition of an internal peptide complex, MHC class II molecule, to affect the immune response of the subject mammal. A method of using a pharmaceutical peptide in a pharmaceutically amount that can be used. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900702013A 1989-01-12 1990-01-11 How T-cell Recognized Peptide Modifications Influence the Immune Response Ceased KR910700259A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29621789A 1989-01-12 1989-01-12
PCT/US1990/000085 WO1990008161A1 (en) 1989-01-12 1990-01-11 Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses
US296217 1994-08-25

Publications (1)

Publication Number Publication Date
KR910700259A true KR910700259A (en) 1991-03-14

Family

ID=23141090

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702013A Ceased KR910700259A (en) 1989-01-12 1990-01-11 How T-cell Recognized Peptide Modifications Influence the Immune Response

Country Status (3)

Country Link
KR (1) KR910700259A (en)
AU (1) AU4948890A (en)
WO (1) WO1990008161A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5679640A (en) * 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
WO1993005011A1 (en) * 1991-08-29 1993-03-18 Sandoz Ltd. Novel immunosuppressants
FR2722207B1 (en) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med METHOD FOR GENERATING A POPULATION OF CELLS HAVING A HIGH DENSITY ON A SURFACE OF A SPECIFIC EXOGENOUS PEPRIDE ASSOCIATED WITH AZX MHC MOLECULES; CELL POPULATION
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) * 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera

Also Published As

Publication number Publication date
WO1990008161A1 (en) 1990-07-26
AU4948890A (en) 1990-08-13

Similar Documents

Publication Publication Date Title
KR950700728A (en) Pharmaceutical and other dosage forms
RU94046251A (en) Glucagon-like peptide and derivatives of insulinotropine, method of synthesis, pharmaceutical compositions, method of diabetes treatment
ATE425181T1 (en) THERAPEUTIC COMPOSITIONS OF ANTIBODIES AND ANTISENS NUCLEIC ACIDS AGAINST SERRATE
ATE167396T1 (en) AGENTS FOR THE ORAL ADMINISTRATION OF ACTIVE INGREDIENTS
KR910002897A (en) Erythropoietin (EPO) Peptides and Antibodies
BR9702179A (en) Conjugated process for treating a disease in a mammal and pharmaceutical composition
ATE144704T1 (en) AGENT FOR TOPICAL ADMINISTRATION OF MEDICINAL INGREDIENTS
DK395689D0 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF DIABETES MELLITUS
DK0470117T3 (en) Use of "calcitonin gene-related peptides" for the manufacture of drugs for the treatment of erectile dysfunctions
DK0506748T3 (en) Amino acids, peptides or derivatives thereof bound to fats
FR2768341B1 (en) LYOPHILISABLE PLACEBO PHARMACEUTICAL COMPOSITION FOR IMITATING A MEDICAMENT, IN PARTICULAR BASED ON PROTEINS OR POLYPEPTIDES
KR910700259A (en) How T-cell Recognized Peptide Modifications Influence the Immune Response
DE68927379D1 (en) SLIDE BLOCKING PEPTIDES
DK0707473T3 (en) Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymer beads
DE69025211D1 (en) Protein anti-cancer drug
ATE338819T1 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
GB2020665A (en) Acyl-N-acetylmuramylpeptide- antigen conjugate
KR900701298A (en) Peptides with T-Cell Inhibitory Activity
FR2694938B1 (en) NOVEL PEPTIDES, ANTIBODIES DIRECTED AGAINST SUCH PEPTIDES, ANTI-IDIOTYPIC ANTIBODIES, APPLICATION AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC KITS CONTAINING THEM.
KR890009972A (en) Peptides, methods of preparation thereof, their use to obtain antibodies, and the use of antibodies to inhibit PAI 1 activity in human blood
Cantalamessa et al. Effects of chronic administration of eldoisin or physalaemin on the rat salivary glands
FR2665363B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING BLEOMYCIN (S) AND BLEOMYCIN-INACTIVE PROTEIN (S).
NO952608L (en) Derivatized calcitonins
KR930002375A (en) Ribotoxin Protein
KR880010122A (en) Improved Cell Toxin

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900912

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950111

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900912

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19971127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19971127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I